PVG Asset Management Corp Takes Position in BioLineRx Ltd. (NASDAQ:BLRX)

PVG Asset Management Corp purchased a new position in shares of BioLineRx Ltd. (NASDAQ:BLRX) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 123,580 shares of the biotechnology company’s stock, valued at approximately $70,000. PVG Asset Management Corp owned about 0.15% of BioLineRx as of its most recent SEC filing.

Separately, CVI Holdings LLC acquired a new position in shares of BioLineRx during the second quarter valued at approximately $462,000. 1.56% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, June 3rd.

BioLineRx Stock Performance

NASDAQ:BLRX opened at $0.54 on Tuesday. BioLineRx Ltd. has a twelve month low of $0.51 and a twelve month high of $1.93. The company has a market cap of $42.86 million, a P/E ratio of -0.71 and a beta of 1.46. The company has a current ratio of 1.61, a quick ratio of 1.49 and a debt-to-equity ratio of 1.34. The company’s 50-day moving average price is $0.69 and its 200-day moving average price is $0.72.

BioLineRx (NASDAQ:BLRX) last issued its earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. The company had revenue of $5.39 million for the quarter, compared to analyst estimates of $3.93 million. On average, sell-side analysts forecast that BioLineRx Ltd. will post -0.25 earnings per share for the current fiscal year.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.